Details
Therapeutic categorythe type of treatment or therapy being studied. A therapy could range from a medication addressing a particular characteristic of CF to a device or activity e.g. exercise
Other
Full title
Gastro-oesphageal reflux in patients with cystic fibrosis and its effect on lung function: an observational study
Gastro - oesophageal reflux disease(GORD) is a condition where acid from the stomach leaks out of the stomach and up into the oesophagus (gullet) It is common in patient with Cystic Fibrosis. Although symptoms such as heartburn and acid taste in the mouth can occur, often there are no symptoms. Studies have suggested a link between a worsening lung function and the amount of GORD. A potential mechanism is by the stomach content travelling into the lungs causing inflammation and altering the usual organisms that are present. If that is the case, there may be opportunities for new drugs and /or surgical procedures. The aim of this observational study is to investigate if GORD affects the lung function. The study will assess mircobiology and presence of markers of reflux aspiration. These are substances that are found in the gastrointrestinal tract and that , if detected in sputum, support the presence of stomach contents in the lungs. In addition factors that may influence GORD such as antacids tablets and enteral feeding ( via a tube into the stomach) will be evaluated. GORD will be measured by using special probes that assess the function of the oesophagus, PH (acidity) and presence of gastic contents within the gullet. The participants will provide measures of lung function, clinical details, blood, and sputum samples as well as complete symptoms questionnaires
Trial Reference Number
105287
Trial type
Non-medication
Length of participationthe length of time a participant will take part in a trial, from the first to the last appointment
24 hours
Last edited date
16 May 2019
CF sponsor
University Hospital South Manchester
CF sponsor type
Academic
Add to watchlist